EPHA2 and pancreatic neoplasm: Notably, when positive and negative rates for EphA2-NF and CA19-9 were examined in early and late-stage pancreatic cancers, approximately 20% of CA19-9–low pancreatic cancer (<37 U/mL) cases exceeded the EphA2-NF cutoff (≥50 pg/mL; Supplementary Fig. S5), and no significant correlation was found between EphA2-NF and CA19-9 levels (Fig. 4C).